Dr. Oratz on PARP Inhibitors to Treat Patients With Breast Cancer

Video

Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.

Cancer Network spoke with Ruth Oratz, MD, a medical oncologist and breast cancer specialist at NYU Langone Perlmutter Cancer Center in New York City, about the use of poly (ADP-ribose) polymerase inhibitors for patients diagnosed with breast cancer. 

Recent Videos
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
Related Content
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

Allireza Alloo, MD

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Tim Cortese
October 27th 2025
Article

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.